Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Sep 18, 2024 12:11pm
93 Views
Post# 36229161

RE:RE:RE:RE:RE:RE:RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer

RE:RE:RE:RE:RE:RE:RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancerFor some reason mr. Qu30, keeps stating " they have the data"
Unless, he/ she is part if the trial clinics & evaluating teams, there is 100% no way to prove or unproven " they have the data".
Most importantly along that line, the trial is not run by Onc.
There are multiple recording, collecting & analysts of data required.
Seeing on the fda page the trial is over on xx date, Could / might mean many things.
For example, that date could be the close out if final treatment,
Repeating again the outcomes, specifically overall survival depends on people passing away.
Unless  the trial includes murder or assisted suicide, it is impossible to determine when someone will die.
so to spout off why there are hiding results & making conclusive statements, is extreamly missleading.
One very significant point. Any " published" reults of the significance we are talking about, would be peer reviewed, 
Meaning even after all the post mortality analysis, conclusions would be formalized based on the context of the trial.
THEN, a third party of qualified PHDs would review the data & conclusions.
Moving the lens further out; Does Onc mangement have a reasonable idea of the outcomes. Absolutely.
Their published on- line presentation says results will be available before the end of  this year.
That is the only thing we know for sure.
saying anything different, without qualifying as " your opinion" is just not correct.
considering people's lives & the future of  Oncs MBc treatment opportunity is on the line, There will be many layers if reviews etc, long before the results are made public.
Repeating my qualifications to comment. I was a patient as part of a clinical phase 2-b.
It had nothing to do with cancer.
The application process alone was 6 pages of extremely medical details.
Then, a pre- registration interview.
I did not proceed. Personl health reasons.
Had I proceeded there would have been a huge regime of medical exams. Weekly phine interviews.
on & on, all before even getting to the trial of a double blind drug treatment.
Post treatment ( when the trial time would be over...meaning no more treatments), the follow- up included 6 months of post trial medicals etc etc.
My whole point?
The bracelet trial might be indicating as over. The results?
lots of followup , before any official data can be published.
please, don't spout your opinions as apparently factual.
Other then that, we wait.





<< Previous
Bullboard Posts
Next >>